HEALTH POLICY BRIEF — Monday, August 3

Executive Briefing

ONC moved the electronic-prior-authorization standards stack forward—and left an implementation-sequencing problem behind. In the FY 2027 IPPS final rule, ONC finalized updated versions of seven FHIR implementation guides, including Da Vinci CRD 2.2.1, DTR 2.2.0, and PAS 2.2.1. The regulatory standards replace the older versions on October 1. CMS did not, however, finalize payer-API conformance dates here; those remain for the later CMS-0062 final rule.

- Policy relevance: The standards foundation is changing before the operational payer timeline is settled.

- Physician policy angle: This is not an October 1 compliance deadline for practices. The risk is version fragmentation among payers, EHRs, intermediaries, and apps—with small practices left holding the troubleshooting bag. Coordinate vendor-readiness work now and press for aligned testing, clear dates, and payer/vendor responsibility in the later rule. ONC fact sheet (https://healthit.gov/resources/onc-finalizes-the-adoption-of-certain-health-it-standards-in-the-fy2027-cms-ipps-final-rule/) | Final rule (https://www.federalregister.gov/public-inspection/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the)

CMS is taking mandatory joint-replacement episodes national. The same final rule creates CJR-X beginning January 1, 2028, making covered acute-care hospitals—with limited exclusions—accountable for cost and quality from a lower-extremity joint-replacement encounter through 90 days after discharge. CMS also finalized TEAM changes affecting episode triggers, quality measurement, and target-price construction; it estimates CJR-X will save Medicare $725 million over five performance years.

- Policy relevance: The hospital is the accountable entity, but physician alignment, referral patterns, financial arrangements, data sharing, and downstream care will determine how the model actually behaves.

- Physician policy angle: Prepare a focused physician-impact map before implementation guidance arrives, with special attention to independent and smaller practices that may be asked to accept workflow or financial risk without equivalent negotiating leverage. CMS/ONC final rule (https://www.federalregister.gov/public-inspection/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the)

HRSA has revived the 340B rebate pilot, this time with more guardrails and the same basic cash-flow fight. After the 2025 pilot was vacated and remanded, HRSA issued a revised model covering selected Medicare-negotiated drugs. Manufacturer plans are due August 24, approvals are expected by September 24, and approved plans begin January 1, 2027. The August 24 date is a manufacturer application deadline, not a reopened public-comment period. Required safeguards include manufacturer-paid submission platforms, 90 days' notice to covered entities, a minimum 45-day claims-submission window, ten-calendar-day payment or documented denial, limited data fields, and privacy/security protections.

- Policy relevance: The model replaces an upfront discount with claims-based reimbursement for participating drugs; that changes who fronts the money and who bears reconciliation risk.

- Physician policy angle: Flag this today to 340B, rural, FQHC, and drug-policy colleagues. The practical test is whether the guardrails prevent liquidity, vendor, data, and appeal burdens from migrating to safety-net providers. Federal Register notice (https://www.federalregister.gov/documents/2026/08/03/2026-15633/notice-regarding-340b-rebate-model-pilot-program)

Congress / Hearings / Oversight

No fresh congressional hearing, markup, or oversight development cleared the changed-state threshold this morning.

Digital Health / Privacy / Interoperability

ONC's June HIO survey brief, newly promoted by the official account Friday, offers useful enforcement evidence. Seventy-one percent of HIOs reported some potential information blocking in 2025, down from 91% in 2019. Developer fees remained the most frequently reported practice at 59%, and the data suggest the problem is becoming less broad but more concentrated among recurring actors.

- Policy relevance: The numbers support a more targeted enforcement and vendor-accountability argument—not a victory lap.

- Physician policy angle: Add the findings to information-blocking evidence files, especially for work on unreasonable fees, recurring bad actors, and exchange friction that practices cannot solve themselves. ONC data brief (https://healthit.gov/data/data-briefs/trends-in-health-information-organizations-experiences-of-perceived-information-blocking-2019-2025/)

Signal Scan

The X scan completed with findings; it did not time out. Its strategic contribution was surfacing ONC's official July 31 posts, which led to the verified standards and information-blocking items above. Third-party chatter did not add a separate primary-source development and was suppressed.

Policy Action Implications

- Convene a quick prior-authorization/standards/EHR/payer check on readiness for the October 1 FHIR-version replacement; develop CMS-0062 asks around aligned testing and responsibility for conversion costs.

- Build a CJR-X/TEAM physician-impact matrix covering participation, financial arrangements, referrals, data access, and protection for independent practices.

- Route the 340B pilot notice to drug-policy and safety-net colleagues today; review the August 24 window and test the ten-day payment, denial, platform, and privacy safeguards against real provider workflows.

- Save ONC's HIO findings as evidence for targeted information-blocking and vendor-fee advocacy; no immediate filing is required.

Routine hospice and IRF payment updates were screened but did not present a sufficiently strong same-day physician-policy hook for this publication's coverage focus.